Phosphagenics appoints pharma veteran

By Dylan Bushell-Embling
Tuesday, 08 July, 2008

Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.

Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.

Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.

Ashton also served as CEO for SkyePharma PLC.

TGA acts on melatonin imports with infringement notices totalling $99K

Laboratory testing of several imported unregistered melatonin products has confirmed them to be...

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

Content from other channels on our network

Lactalis plans to close dairy factory in Gippsland, ADF comments

Frog peptide could increase the shelf life of strawberries

NZ food scientist recognised for impactful protein study

AIP appoints its new President

foodpro 2026 opens on Sunday

Social media behind almost half of racism and discrimination complaints, Ahpra says

OTs, medical students respond to Commonwealth Prac Payment expansion

HIC returns to Sydney in August

New ACMA SMS rules now in force — could patients be missing vital updates?

A Day in the Life of Prue Walker

$32 million investment to create jet fuel from forest waste

Australia's data centre future will be built on concrete — so make it more sustainable

WA wind farm to generate power for 100,000 homes

Ampd launches next-gen battery storage for heavy industries

Green hydrogen production receives boost using low-cost materials